Cancer research

CYPIDES

This is a phase 1 safety and pharmacokinetics study with ODM-208 trial medication in patients with metastatic castration-resistant prostate cancer.

Principal investigator: Tapio Utriainen

https://clinicaltrials.gov/ct2/show/NCT03436485  

BAYER20511

Open-label multicenter study to assess radium-223 bio-distribution in participants with bone metastatic castration-resistant prostate cancer

Principal Investigator: Katriina Peltola

https://clinicaltrials.gov/ct2/show/NCT04521361

KEYNOTE-991

A phase 3, randomized, double-blind trial of pembrolizumab (MK-3475), enzalutamide and androgen deprivation therapy (ADT) versus placebo, enzalutamide and ADT in participants with metastatic hormone-sensitive prostate cancer

Principal Investigator: Katriina Peltola

https://clinicaltrials.gov/ct2/show/NCT04934722

No ongoing studies at this time.

MK-3475-C93

A Phase 3 Randomized, Open-label, Active-comparator Controlled Clinical Study of Pembrolizumab Versus Platinum Doublet Chemotherapy in Participants With Mismatch Repair Deficient (dMMR) Advanced or Recurrent Endometrial Carcinoma in the First-line Setting

Principal Investigator: Heini Lassus

NIS793B12301

A phase III, randomized, double-blind study in which NIS793 or placebo has been combined with gemsitabine/nab-paclitaxel chemotherapy in first-line treatment of metastatic pancreatic ductal adenocarcinoma (mPDAC).

Principal investigator: Katriina Peltola

https://clinicaltrials.gov/ct2/show/NCT04935359

ALL (ACUTE LYMPHOBLASTIC LEUKEMIA)

ALLTOGETHER

A treatment study protocol of children (1–17 years of age) and young adults (18–45 years of age) with acute lymphoblastic leukemia (ALL)

Person responsible for the study: Ulla Wartiovaara-Kautto

https://clinicaltrials.gov/ct2/show/NCT04307576

EWALL-PH-03

An open label, three-arm, randomized phase II study to compare the safety and efficacy of ponatinib in combination with either chemotherapy or blinatumomab with imatinib plus chemotherapy as primary therapy for patients aged 55 years and older who have Philadelphia chromosome-positive (Ph+ or BCR- ABL1+) acute lymphoblastic leukemia (ALL)

Person responsible for the study: Kimmo Porkka

https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-0033…

SCANALL

SCAN ALL – Nordic study on the occurrence of mutations in patients with Philadelphia chromosome-positive acute lymphocytic leukemia (Ph+ALL) and chronic myeloid leukemia (CML)

Person responsible for the study: Kimmo Porkka

AML (ACUTE MYELOID LEUKEMIA)

BEXMAB

A phase l/ll open-label study to assess safety, tolerability and preliminary efficacy of the clever-1 antibody bexmarilimab in combination with azacitidine or azacitidine/venetoclax in patients with myelodysplastic syndrome or chronic myelomonocytic leukemia or acute myeloid leukemia.

Principal Investigator: Mika Kontro

https://www.clinicaltrialsregister.eu/ctr-search/trial/2021-002104-12/FI

CVOB560A12101

A phase 1b multicenter study of VOB560 study preparation in combination with MIK665 study preparation in patients with relapsed or refractory non-Hodgkin’s lymphoma (NHL), acute myeloid leukemia (AML), or multiple myeloma (MM)

Person responsible for the study: Kimmo Porkka

https://www.clinicaltrials.gov/ct2/show/NCT04702425

HO150, AMLSG 29-18

An open-label, randomized, double-blind placebo-controlled multicenter study of ivosidenib or enasidenib in combination with induction and consolidation chemotherapy followed by a maintenance therapy in patients with newly diagnosed IDH1- or IDH2-mutated acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS-EB2) with excess blasts, and who are eligible for intensive chemotherapy.

Person responsible for the study: Mika Kontro

https://clinicaltrials.gov/ct2/show/NCT03839771

HO156, AMLSG 28-18

A phase III open-label, randomized multicenter study with gilteritinib or midostaurine in combination with induction and consolidation chemotherapy followed by a one-year maintenance treatment period in patients with newly diagnosed FLT3-mutated acute myeloid leukemia (AML) or myelodysplastic syndrome with excess blasts (MDS-EB2), and who are eligible for intensive chemotherapy.

Person responsible for the study: Mika Kontro

https://clinicaltrials.gov/ct2/show/NCT03839771

LOXO-IDH-20001

A phase 1 study for assessment of oral LY3410738 in patients with advanced hematologic malignancies with IDH1 or IDH2 mutations

Person responsible for the study: Kimmo Porkka

https://clinicaltrials.gov/ct2/show/NCT04603001

MYELOFIBROSIS

INCB 57643-103

Open-label phase I study on the safety and tolerability of INCB57643 in subjects with myelofibrosis

Person responsible for the study: Minna Lehto

https://clinicaltrials.gov/ct2/show/NCT04279847

INCB 50465-304

Randomized, double-blind, placebo-controlled study on the use of the combination of PI3Kδ inhibitor parsaclisib and ruxolitinib in participants with myelofibrosis who have suboptimal response to ruxolitinib

Person responsible for the study: Minna Lehto

https://clinicaltrials.gov/ct2/show/NCT04551053

INCB 50465-313

Phase 3 randomized, double-blind, placebo-controlled study on the use of the combination of PI3Kδ inhibitor parsaclisib and ruxolitinib in participants with myelofibrosis

Person responsible for the study: Minna Lehto

https://clinicaltrials.gov/ct2/show/NCT04551066

MYELOMA

CC-92480-MM-001

Open-label study to assess the safety, pharmacokinetics and preliminary efficacy of CC-92480 in combination with dexamethasone in subjects with relapsed and refractory multiple myeloma

Person responsible for the study: Pekka Anttila

https://clinicaltrials.gov/ct2/show/NCT03374085

COBRA

Phase 3 randomized open-label study comparing combination Crd and Vrd medications (carfilzomicb + lenalidomide + dexamethasone vs. bortezomib + lenalidomide + dexamethasone) in the treatment of newly diagnosed multiple myeloma

Person responsible for the study: Juha Lievonen

https://clinicaltrials.gov/ct2/show/NCT03729804

CARTITUDE-5

A Phase 3 Randomized Study Comparing Bortezomib, Lenalidomide and Dexamethasone (VRd) followed by Ciltacabtagene Autoleucel, a Chimeric Antigen Receptor T cell (CAR-T) Therapy Directed Against BCMA versus Bortezomib, Lenalidomide, and Dexamethasone (VRd) followed by Lenalidomide and Dexamethasone (Rd) Therapy in Participants with Newly Diagnosed Multiple Myeloma for Whom Hematopoietic Stem Cell Transplant is Not Planned as Initial Therapy.

Principal Investigator: Mikko Keränen

https://clinicaltrials.gov/ct2/show/NCT04923893

MagnetisMM-5

An open-label, 3-arm, multicenter, randomized Phase 3 study to evaluate the efficacy and safety of elranatamab (PF-06863135) monotherapy and elranatamab + daratumumab versus daratumumab + pomalidomide + dexamethasone in participants with relapsed/refractory multiple myeloma who have received at least 1 prior line of therapy including lenalidomide and a proteasome inhibitor.

Principal Investigator: Juha Lievonen

https://clinicaltrials.gov/ct2/show/NCT05020236

MagnetisMM-7 

A randomized, 2-arm, phase 3 study of elranatamab (PF-06863135) versus lenalidomide in patients with newly diagnosed multiple myeloma who are minimimal residual disease positive after undergoing autologous stem-cell transplantation.

Principal Investigator: Juha Lievonen

https://clinicaltrials.gov/ct2/show/NCT05317416

CLL (CHRONIC LYMPHOCYTIC LEUKEMIA)

CJBH492A12101

Description of the study: Open-label study on treatment with JBH492 in patients with relapsed or refractory chronic lymphocytic leukemia (CLL) and non-Hodgkin’s lymphoma (NHL)

Person responsible for the study: Vesa Lindström

https://clinicaltrials.gov/ct2/show/NCT04240704 

ASTEROID

Open-label randomized phase II study in which durvalumab is administered after stereotactic body radiotherapy as adjuvant therapy to non-small cell, grade I lung cancer

Principal investigator: Anu Anttonen

https://clinicaltrials.gov/ct2/show/NCT03446547

-

NP30179

Phase I open-label multicenter study assessing the safety, tolerability and pharmacokinetics of RO7082859 when administered as a single agent and in combination with obinutuzumab at escalating doses to subjects with relapsed or refractory B-cell non-Hodgkin’s lymphoma who have received a fixed single dose pre-treatment of obinutuzumab

Principal investigator: Sirpa Leppä

https://clinicaltrials.gov/ct2/show/NCT03075696 

POLAR BEAR

An open-label randomized phase III study comparing R-MINI-CHOP to R-MINI-CHP therapy in combination with polazuzumab-vedotin as primary treatment for elderly patients with diffuse large cell B-cell lymphoma.

Principal investigator: Sirpa Leppä

https://clinicaltrials.gov/ct2/show/NCT04332822

CJBH492A12101

Multicenter phase I/Ib open-label study with JBH492 at escalating doses in patients with recurrent or refractory chronic lymphocytic leukemia (CLL) and non-Hodgkin’s lymphoma (NHL)

Principal investigator: Sirpa Leppä

https://clinicaltrials.gov/ct2/show/NCT04240704

GCT3013-01

Phase 1/2 open-label dose-escalation study with GEN3013 in patients with relapsed, progressive or refractory B-cell lymphoma

Principal investigator: Sirpa Leppä

https://clinicaltrials.gov/ct2/show/NCT03625037

GCT3013-02

Phase 1b/2 open-label study to assess the safety and preliminary efficacy of epcoritamab (GEN3013; DuoBody-CD3xCD20®) in combination with other agents in subjects with B-cell non-Hodgkin’s lymphoma

Principal investigator: Sirpa Leppä

https://clinicaltrials.gov/ct2/show/NCT04663347

GCT3013-05

Randomized, open-label phase 3 study to assess the efficacy of epkoritamab compared to investigator’s choice chemotherapy in patients with relapsed or refractory diffuse large B-cell lymphoma

Principal investigator: Sirpa Leppä

https://clinicaltrials.gov/ct2/show/NCT04628494

XHUTCHISON 2018-689-00US1

Open-label phase 1 study to evaluate the safety, tolerability, pharmacokinetics and preliminary efficacy of HMPL-689 in patients with relapsed or refractory lymphoma

Principal investigator: Sirpa Leppä

https://clinicaltrials.gov/ct2/show/NCT03786926
 

ALTAMIRA

Acalabrutinib and rituximab in elderly patients with untreated mantle cell lymphoma

Principal Investigator: Annika Pasanen

https://clinicaltrials.gov/ct2/show/NCT05214183

INCMOR 0208-301

A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Tafasitamab Plus Lenalidomide in Addition to Rituximab Versus Lenalidomide in Addition to Rituximab in Patients With Relapsed/Refractory (R/R) Follicular Lymphoma Grade 1 to 3a or R/R Marginal Zone Lymphoma

Principal Investigator: Annika Pasanen

CA030-001

Phase 1/2 first-in-human study of BMS-986249 alone and in combination with nivolumab in advanced solid tumors

Principal investigator: Micaela Hernberg

https://clinicaltrials.gov/ct2/show/NCT03369223

CA022-001

Phase 1/2a first-in-human study of BMS-986218 monoclonal antibody alone and in combination with nivolumab in advanced solid tumors.

Principal investigator: Micaela Hernberg

https://clinicaltrials.gov/ct2/show/NCT03110107

EORTC 1612-MG

Combination of targeted therapy (encorafenib and binimetinib) followed by combination of immunotherapy (ipilimumab and nivolumab) versus immediate combination of immunotherapy in patients with inoperable or metastatic melanoma with BRAF V600 mutation: an EORTC randomized phase II study (EBIN), 1612-MG

Principal investigator: Micaela Hernberg

https://clinicaltrials.gov/ct2/show/NCT03235245

STARBOARD

A Phase 3, Randomized, Double-blind Study of Encorafenib and Binimetinib Plus Pembrolizumab Versus Placebo Plus Pembrolizumab in Participants With BRAF V600E/K Mutation-Positive Metastatic OR Unresectable Locally Advanced Melanoma

Principal Investigator: Micaela Hernberg

https://clinicaltrials.gov/ct2/show/NCT04657991
 

MK6482-005

An open-label, randomized phase 3 study of MK-6482 versus everolimus in participants with advanced renal cell carcinoma that has progressed after prior treatment.

Principal investigator: Katriina Peltola

https://clinicaltrials.gov/ct2/show/NCT04195750

MK6482-011

Drug study comparing the MK-6482 study preparation and the combination of lenvatinib and kabotzantinib in advanced renal cell carcinoma

Principal investigator: Katriina Peltola

https://clinicaltrials.gov/ct2/show/NCT04586231

MK6482-012

An open-label randomized phase 3 study on the efficacy and safety of a combination therapy of pembrolizumab, lenvatinib and beltsutifan (MK-6482) compared to a combination therapy of MK-1308A and lenvatinib or a combination therapy of pembrolizumab and lenvatinib in advanced renal cell carcinoma

Principal investigator: Katriina Peltola

https://clinicaltrials.gov/ct2/show/NCT04736706
 

MK6482-022

A Multi-center, Double-Blind, Randomized Phase 3 Study to Compare Efficacy and Safety of Belzutifan (MK-6482) plus Pembrolizumab Versus Placebo plus Pembrolizumab, in the Adjuvant Treatment of Clear Cell Renal Cell Carcinoma (ccRCC) Post-Nephrectomy

Principal Investigator: Katriina Peltola

https://www.clinicaltrials.gov/ct2/show/NCT05239728

KRYSTAL-10

A Randomized Phase 3 Study of MRTX849 in Combination With Cetuximab Versus Chemotherapy in Patients With Advanced Colorectal Cancer With KRAS G12C Mutation With Disease Progression On or After Standard First-Line Therapy

Principal Investigator: Siru Mäkelä

https://clinicaltrials.gov/ct2/show/NCT04793958

BREAKWATER 

Open-label, multicenter, randomized phase 3 study of first-line Encorafenib plus Cetuximab with or without chemotherapy versus standard of care therapy with a safety lead-in of Encorafenib and Cetuximab plus chemotherapy in participants with metastatic BRAF V600E-mutant colorectal cancer 

Principal Investigator: Siru Mäkelä
https://clinicaltrials.gov/ct2/show/NCT04607421

ZEST

Study assessing the efficacy and safety of niraparib compared to placebo in breast cancer patients with tumor DNA in their blood after definitive therapy (ZEST study)

Principal investigator: Tytti Ahola

https://clinicaltrials.gov/ct2/show/NCT04915755

Advanced breast cancer

MO42319 KATE3

Phase III randomized, double-blind, placebo-controlled multicenter study to assess the efficacy and safety of combination therapy containing trastuzumab emtansine and atezolisumab or placebo in subjects with HER2-positive and PD-L1 positive locally advanced or metastatic breast cancer who have previously received trastuzumab (and possibly pertuzumab) and taxane-based therapy (KATE3)

Principal investigator: Meri Utriainen

https://clinicaltrials.gov/ct2/show/NCT04740918

DESTINY

An open-label, multinational, multicenter, phase 3b/4 study on trastuzumab-deruxstecan in patients with previously treated locally advanced / distantly metastasized HER2-positive breast cancer, with or without baseline brain metastasis  (DESTINY - Breast12)

Principal investigator: Johanna Mattson

https://clinicaltrials.gov/ct2/show/NCT04739761

Early breast cancer

Effects of Vaginal Estrogens on Serum Estradiol Levels in Postmenopausal Women with Breast Cancer Taking an Aromatase Inhibitor

Principal Investigator: Maria Faltinova

https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-0012…

LIDERA

A phase III, randomized, open-label, multicenter study evaluating the efficacy and safety of adjuvant giredestrant compared with physician's choice of adjuvant endocrine monotherapy in patients with estrogen receptor-positive, HER2-negative early breast cancer

Principal Investigator: Peeter Karihtala

https://clinicaltrials.gov/ct2/show/NCT04961996

BRIGHTLINE-1

Brightline-1: A Phase II/III, Randomized, Open-label, Multi-center Study of BI 907828 Compared to Doxorubicin as First Line Treatment of Patients With Advanced Dedifferentiated Liposarcoma

Principal Investigator: Kirsi Santti

https://clinicaltrials.gov/ct2/show/NCT05218499 

FINPROVE

A national phase 2 drug study on individual cancer treatment in advanced cancer.

Principal investigator: Katriina Peltola

https://clinicaltrials.gov/ct2/show/NCT05159245

MATINS

Phase I/II open-label, three-phase study to determine tolerated dose and follow-up separate cohorts to assess the safety, tolerability and preliminary efficacy of CLEVER-1 antibody FP-1305 in subjects with advanced cancer (gastrointestinal cancer, melanoma or ovarian cancer)

Principal investigator: Annika Pasanen

https://clinicaltrials.gov/ct2/show/NCT03733990

TILT

Phase I dose-escalation study to determine the safety of tumor necrosis factor alpha and interleukin-2 cytokine-coding oncolytic adenovirus (TILT-123) in patients with injectable solid tumor refractory to other therapies

Principal investigator: Katriina Peltola

https://clinicaltrials.gov/ct2/show/NCT04695327

-

The Comprehensive Cancer Center has currently approximately 150 ongoing studies, of which drug trials are a significant portion. In all our research activities, we adhere to the best ethical principles. We carry out the studies in accordance with good clinical practice, considering the interests of the research patient a priority. In our research activities, we also follow the Declaration of Helsinki. 

New studies can be offered to the Comprehensive Cancer Center by sending a message to uudetsyopatutkimukset@hus.fi, or directly to the researcher.

Obtaining a hospital research permit for a pharmaceutical trial requires the approval of the Ethics Committee and FIMEA, as well as a financial agreement. The total duration of the permit processing from the research offer to its approval is approximately two months. Permits and agreements can be prepared and processed simultaneously.